SCHEDULE 13G/A: BlackRock Discloses 5.3% Passive Stake in Allogene Therapeutics
Beneficial Ownership Filing
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in Allogene Therapeutics, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 11,450,079 shares of Allogene Therapeutics, Inc. common stock.
- This represents 5.3% of the outstanding common stock of Allogene Therapeutics, Inc.
- BlackRock, Inc. holds sole voting power over 11,294,846 shares and sole dispositive power over 11,450,079 shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in previously reported ownership or status.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing disclosing beneficial ownership. It contains no positive or negative operational or financial news, thus a neutral sentiment score is appropriate.
Industry Context
This filing indicates a significant passive investment by BlackRock, one of the world's largest asset managers, in Allogene Therapeutics, a company operating in the biotechnology and therapeutics sector. Such a substantial stake from a major institutional investor can signal long-term confidence in the company's prospects, although Schedule 13G filings are typically for passive investment purposes and do not imply active management involvement.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was expressly revoked by the new Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement, representing the reporting period end date for the beneficial ownership. |
| 2025-04-17 | Date the Schedule 13G filing was signed by BlackRock, Inc. |
Keywords
BlackRock, Allogene Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.